Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1High Grade Cervical Intraepithelial Neoplasia 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Rituximab 43Cyclophosphamide 26fludarabine 15ibrutinib 14Vincristine 11Prednisone 11Doxorubicin 11pirtobrutinib 10Bendamustine Hydrochloride 10obinutuzumab 9polatuzumab vedotin 6Inotuzumab Ozogamicin 6tocilizumab 5pembrolizumab 5glofitamab 5Gemcitabine 5zanubrutinib 4venetoclax 4ublituximab 4Lenalidomide 4Brentuximab Vedotin 4Antigens, CD19 4tazemetostat 3acalabrutinib 3Everolimus 3DTRMWXHS-12 3veltuzumab 2sepantronium 2iberdomide 2denileukin diftitox 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell × Biological Products × Clear all
NCT03383952 2017-12-27

A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡